BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dong S, Zhan ZY, Cao HY, Wu C, Bian YQ, Li JY, Cheng GH, Liu P, Sun MY. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(15): 2771-2784 [PMID: 28487615 DOI: 10.3748/wjg.v23.i15.2771] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Del Ben M, Overi D, Polimeni L, Carpino G, Labbadia G, Baratta F, Pastori D, Noce V, Gaudio E, Angelico F, Mancone C. Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. Int J Mol Sci 2018;19:E603. [PMID: 29463024 DOI: 10.3390/ijms19020603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Robinson EJ, Taddeo MC, Chu X, Shi W, Wood C, Still C, Rovnyak VG, Rovnyak D. Aqueous Metabolite Trends for the Progression of Nonalcoholic Fatty Liver Disease in Female Bariatric Surgery Patients by Targeted 1H-NMR Metabolomics. Metabolites 2021;11:737. [PMID: 34822395 DOI: 10.3390/metabo11110737] [Reference Citation Analysis]
3 Wishart DS. Metabolomics for Investigating Physiological and Pathophysiological Processes. Physiol Rev 2019;99:1819-75. [PMID: 31434538 DOI: 10.1152/physrev.00035.2018] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 32.7] [Reference Citation Analysis]
4 Niu L, Sulek K, Vasilopoulou CG, Santos A, Wewer Albrechtsen NJ, Rasmussen S, Meier F, Mann M. Defining NASH from a Multi-Omics Systems Biology Perspective. J Clin Med 2021;10:4673. [PMID: 34682795 DOI: 10.3390/jcm10204673] [Reference Citation Analysis]
5 Castillo-Castro C, Martagón-Rosado AJ, Ortiz-Lopez R, Garrido-Treviño LF, Villegas-Albo M, Bosques-Padilla FJ. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World J Hepatol 2021; 13(11): 1494-1511 [PMID: 34904026 DOI: 10.4254/wjh.v13.i11.1494] [Reference Citation Analysis]
6 Moolla A, de Boer J, Pavlov D, Amin A, Taylor A, Gilligan L, Hughes B, Ryan J, Barnes E, Hassan-Smith Z, Grove J, Aithal GP, Verrijken A, Francque S, Van Gaal L, Armstrong MJ, Newsome PN, Cobbold JF, Arlt W, Biehl M, Tomlinson JW. Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome. Aliment Pharmacol Ther 2020;51:1188-97. [PMID: 32298002 DOI: 10.1111/apt.15710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Gitto S, Schepis F, Andreone P, Villa E. Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives. Metabolites. 2018;8. [PMID: 29495258 DOI: 10.3390/metabo8010017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
8 Mozduri Z, Marty-Gasset N, Lo B, Masoudi AA, Morisson M, Canlet C, Arroyo J, Bonnet A, Bonnefont CMD. Identification of Plasmatic Biomarkers of Foie Gras Qualities in Duck by Metabolomics. Front Physiol 2021;12:628264. [PMID: 33643071 DOI: 10.3389/fphys.2021.628264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zhu M, Li M, Zhou W, Ge G, Zhang L, Ji G. Metabolomic Analysis Identifies Glycometabolism Pathways as Potential Targets of Qianggan Extract in Hyperglycemia Rats. Front Pharmacol 2020;11:671. [PMID: 32477136 DOI: 10.3389/fphar.2020.00671] [Reference Citation Analysis]
10 Sun R, Zhao H, Huang S, Zhang R, Lu Z, Li S, Wang G, Aa J, Xie Y. Prediction of Liver Weight Recovery by an Integrated Metabolomics and Machine Learning Approach After 2/3 Partial Hepatectomy. Front Pharmacol 2021;12:760474. [PMID: 34916939 DOI: 10.3389/fphar.2021.760474] [Reference Citation Analysis]
11 Gurian E, Giraudi P, Rosso N, Tiribelli C, Bonazza D, Zanconati F, Giuricin M, Palmisano S, de Manzini N, Sergo V, Bonifacio A. Differentiation between stages of non-alcoholic fatty liver diseases using surface-enhanced Raman spectroscopy. Anal Chim Acta 2020;1110:190-8. [PMID: 32278395 DOI: 10.1016/j.aca.2020.02.040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68:359-370. [PMID: 30171065 DOI: 10.1136/gutjnl-2018-316307] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 28.8] [Reference Citation Analysis]
13 Yang Q, Zhang A, Miao J, Sun H, Han Y, Yan G, Wu F, Wang X. Metabolomics biotechnology, applications, and future trends: a systematic review. RSC Adv 2019;9:37245-57. [DOI: 10.1039/c9ra06697g] [Cited by in Crossref: 28] [Article Influence: 9.3] [Reference Citation Analysis]
14 Carril E, Valdecantos MP, Lanzón B, Angulo S, Valverde ÁM, Godzien J, Rupérez FJ. Metabolic impact of partial hepatectomy in the non-alcoholic steatohepatitis animal model of methionine-choline deficient diet. J Pharm Biomed Anal 2020;178:112958. [PMID: 31718984 DOI: 10.1016/j.jpba.2019.112958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Perakakis N, Stefanakis K, Mantzoros CS. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 2020;111S:154320. [PMID: 32712221 DOI: 10.1016/j.metabol.2020.154320] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
16 Feng Q, Li Y, Yang Y, Feng J. Urine Metabolomics Analysis in Patients With Normoalbuminuric Diabetic Kidney Disease. Front Physiol 2020;11:578799. [PMID: 33123032 DOI: 10.3389/fphys.2020.578799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Beyoğlu D, Idle JR. Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy. Metabolites 2020;10:E50. [PMID: 32012846 DOI: 10.3390/metabo10020050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
18 Carulli L, Zanca G, Schepis F, Villa E. The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD). Metabolites 2019;9:E25. [PMID: 30717274 DOI: 10.3390/metabo9020025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
19 Wegermann K, Howe C, Henao R, Wang Y, Guy CD, Abdelmalek MF, Diehl AM, Moylan CA. Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021;5:608-17. [PMID: 33860119 DOI: 10.1002/hep4.1665] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gou XJ, Gao S, Chen L, Feng Q, Hu YY. A Metabolomic Study on the Intervention of Traditional Chinese Medicine Qushi Huayu Decoction on Rat Model of Fatty Liver Induced by High-Fat Diet. Biomed Res Int 2019;2019:5920485. [PMID: 30881991 DOI: 10.1155/2019/5920485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
21 Cyr B, Keane RW, de Rivero Vaccari JP. ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study. Int J Mol Sci 2020;21:E8580. [PMID: 33203036 DOI: 10.3390/ijms21228580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Alldritt I, Greenhaff PL, Wilkinson DJ. Metabolomics as an Important Tool for Determining the Mechanisms of Human Skeletal Muscle Deconditioning. Int J Mol Sci 2021;22:13575. [PMID: 34948370 DOI: 10.3390/ijms222413575] [Reference Citation Analysis]
23 Ezzaidi N, Zhang X, Coker OO, Yu J. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer. Cancer Lett 2019;459:186-91. [PMID: 31185249 DOI: 10.1016/j.canlet.2019.114425] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
24 Lawrence YA, Guard BC, Steiner JM, Suchodolski JS, Lidbury JA. Untargeted metabolomic profiling of urine from healthy dogs and dogs with chronic hepatic disease. PLoS One 2019;14:e0217797. [PMID: 31150490 DOI: 10.1371/journal.pone.0217797] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Savic D, Hodson L, Neubauer S, Pavlides M. The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E2178. [PMID: 32708036 DOI: 10.3390/nu12082178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
26 Liu L, Zhao J, Zhang R, Wang X, Wang Y, Chen Y, Feng R. Serum untargeted metabolomics delineates the metabolic status in different subtypes of non-alcoholic fatty liver disease. J Pharm Biomed Anal 2021;200:114058. [PMID: 33865049 DOI: 10.1016/j.jpba.2021.114058] [Reference Citation Analysis]
27 Rodríguez-Morató J, Pozo ÓJ, Marcos J. Targeting human urinary metabolome by LC-MS/MS: a review. Bioanalysis 2018;10:489-516. [PMID: 29561651 DOI: 10.4155/bio-2017-0285] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
28 Masoodi M, Gastaldelli A, Hyötyläinen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, Anstee QM, Millet O, Ortiz P, Mato JM, Dufour JF, Orešič M. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34508238 DOI: 10.1038/s41575-021-00502-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Goon DE, Ab-Rahim S, Mohd Sakri AH, Mazlan M, Tan JK, Abdul Aziz M, Mohd Noor N, Ibrahim E, Sheikh Abdul Kadir SH. Untargeted serum metabolites profiling in high-fat diet mice supplemented with enhanced palm tocotrienol-rich fraction using UHPLC-MS. Sci Rep 2021;11:21001. [PMID: 34697380 DOI: 10.1038/s41598-021-00454-9] [Reference Citation Analysis]
30 Tang T, Li Y, Wang J, Elzo MA, Shao J, Li Y, Xia S, Fan H, Jia X, Lai S. Untargeted Metabolomics Reveals Intestinal Pathogenesis and Self-Repair in Rabbits Fed an Antibiotic-Free Diet. Animals (Basel) 2021;11:1560. [PMID: 34071848 DOI: 10.3390/ani11061560] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ioannou GN, Nagana Gowda GA, Djukovic D, Raftery D. Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach. Metabolites 2020;10:E168. [PMID: 32344559 DOI: 10.3390/metabo10040168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Li W, Yang Y, Dai Q, Lin L, Xie T, He L, Tao J, Shan J, Wang S. Non-invasive urinary metabolomic profiles discriminate biliary atresia from infantile hepatitis syndrome. Metabolomics 2018;14. [DOI: 10.1007/s11306-018-1387-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Ren X, Fan W, Shao Z, Chen K, Yu X, Liang Q. A metabolomic study on early detection of steroid-induced avascular necrosis of the femoral head. Oncotarget 2018;9:7984-95. [PMID: 29487708 DOI: 10.18632/oncotarget.24150] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
34 Kim DJ, Yoon S, Ji SC, Yang J, Kim YK, Lee S, Yu KS, Jang IJ, Chung JY, Cho JY. Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. Sci Rep 2018;8:11874. [PMID: 30089798 DOI: 10.1038/s41598-018-30349-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]